Priavoid

Focus: Priavoid is an early-stage German biotech focused on all-D-peptides for neurology, founded in 2022 and publicly listed. The company is pre-revenue with a single Phase 2 program targeting Alzheimer's disease.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Priavoid

AI assessmentNot Hiring

No open roles listed right now. Follow Priavoid to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PRI-002

Mild Cognitive Impairment Due to Alzheimer's Disease

PHASE_2

Clinical Trials (1)

NCT06182085Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

Phase 2

Help build intelligence for Priavoid

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to emerging all-D-peptide platform technology with only 1 published competitor in this modality space
Ground-floor opportunity at a publicly traded company with potential for significant equity upside if Phase 2 PRI-002 succeeds
Focus on high-unmet-need Alzheimer's disease space with tailwinds from aging populations and regulatory incentives

Watch Out For

No active job openings and minimal hiring activity suggest operational constraints or slow growth trajectory
Extremely early-stage pipeline (1 Phase 2 trial) creates high clinical and commercial risk with limited near-term catalysts
Missing financial data (cash position, R&D spend, revenue) raises transparency concerns for career stability assessment

Generated by Claude from Priavoid's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.